



TISSUE THERAPIES

ASX ANNOUNCEMENT

26 July 2007

Strengthened Financial Position for VitroGro® Human Trials

Biomedical company, **Tissue Therapies Limited (ASX: TIS)** has today closed a placement of 4,040,000 new ordinary shares with institutional and sophisticated investors at \$0.50/share to raise \$2,020,000 before costs of the issue.

The placement of new shares has been conducted in accordance with ASX Listing Rule 7.1 and represents an additional 15.00% of the Company's existing issued capital.

The net proceeds of the issue will provide additional funding to accelerate pre-clinical and regulatory approval work, prior to a more sophisticated human trial of VitroGro® for the treatment of diabetic, venous and pressure ulcers.

As recently announced, exciting new developments since May 2007 have made it clear that the additional preclinical and human trial work will substantially enhance the commercial position of Tissue Therapies in the ongoing negotiations with international health and wound care companies. Please see:

- **VitroGro® Human Trials to Accelerate Commercialisation** 22 May 2007
- **VitroGro® Gets Positive News From Health Canada** 20 June 2007

The placement was managed by ABN AMRO Morgans Limited, manager of the Company's 2004 IPO. Settlement is scheduled for Wednesday 1 August 2007.

Further information:

Dr Steven Mercer
CEO, Tissue Therapies Limited
Telephone: 07 3839 9938

Email: s.mercer@tissuetherapies.com

About Tissue Therapies Limited

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue and various cell culture applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a platform technology developed by tissue engineering experts at the Institute for Health and Biomedical Innovation at QUT for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, stem cell therapies and other cell culture uses.

Based on its VitroGro® platform technology, Tissue Therapies is developing more effective medical treatments for wounds and burns, integration of orthopaedic and medical implants, and other applications such as cosmeceuticals.

Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

More information: www.tissuetherapies.com